Counseling Points Multiple Sclerosis - Winter 2015 - 12

12. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J
Neurosci Nurs. 2001;33(5):231-239.
13. Saunders C, Caon C, Smrtka J, et al. Factors that influence adherence and
strategies to maintain adherence to injected therapies for patients with
multiple sclerosis. J Neurosci Nurs. 2010;42(5 Suppl):S10-18.
14. Kasper J, Heesen C, Köpke S, et al. Patients' and observers' perceptions
of involvement differ. Validation study on inter-relating measures for
shared decision making. PloS One. 2011;6(10):e26255.
15. Best practices for therapeutic selection in remitting relapsing multiple
sclerosis. Int J MS Care. 2014;16(Suppl 5):6-12.
16. Healy BC, Glanz BI, Stankiewicz J, et al. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010;16(12):
1483-1489.
17. Clerico M, Barbero P, Contessa G, et al. Adherence to interferon-beta
treatment and results of therapy switching. J Neurol Sci. 2007;259(12):104-108.
18. Switching disease-modifying therapies due to lack of efficacy. Int J MS
Care. 2014;16(Suppl 5):6-12.
19. Haynes RB, McDonald H, Garg AX, et al. Interventions for helping
patients to follow prescriptions for medications. Cochrane Database Syst
Rev. 2002(2):CD000011.
20. Cohen BA, Khan O, Jeffery DR, et al. Identifying and treating patients
with suboptimal responses. Neurology. 2004;63(12 Suppl 6):S33-40.
21. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1-9.
22. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients
with multiple sclerosis and maintaining treatment adherence in the long
term. Medscape J Med. 2008;10(9):225.
23. Agency for Healthcare Research and Quality. Discontinuation of DiseaseModifying Treatment for Multiple Sclerosis. Research Protocol - Dec 17,
2013. Available at: http://effectivehealthcare.ahrq.gov/index.cfm/searchfor-guides-reviews-and-reports/?productid=1833&pageaction=displaypro
duct.
24. McKelvey C. MS community flares over AHRQ report: controversy erupts
over review of MS drug discontinuation strategies. MedPage Today. Nov
17, 2014. Available at: http://www.medpagetoday.com/Neurology/MultipleSclerosis/48649.

www.counselingpoints.com

25. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug
and missing doses. Pharmacoepidemiol Drug Safety. 2008;17(6):565-576.
26. Halpern R, Agarwal S, Dembek C, et al. Comparison of adherence and
persistence among multiple sclerosis patients treated with diseasemodifying therapies: a retrospective administrative claims analysis. Patient
Prefer Adherence. 2011;5:73-84.
27. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence
with disease-modifying therapy in MS. J Neurol. 2009;256(4):568-576.
28. de Seze J, Borgel F, Brudon F. Patient perceptions of multiple sclerosis
and its treatment. Patient Prefer Adherence. 2012;6:263-273.
29. Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and
other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138.
30. Zeller A, Ramseier E, Teagtmeyer A, et al. Patients' self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertens Res. 2008;31(11):2037-2043.
31. Lugaresi A, Ziemssen T, Oreja-Guevara C, et al. Improving patient-physician dialog: commentary on the results of the MS Choices survey. Patient
Prefer Adherence. 2012;6:143-152.
32. Rinon A, Buch M, Holley D, et al. The MS Choices Survey: findings of a
study assessing physician and patient perspectives on living with and
managing multiple sclerosis. Patient Prefer Adherence. 2011;5:629-643.
33. Bayas A. Improving adherence to injectable disease-modifying drugs in
multiple sclerosis. Expert Opin Drug Deliv. 2013;10(3):285-287.
34. Derose SF, Green K, Marrett E, et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med.
2013;173(1):38-43.
35. Vervloet M, van Dijk L, Santen-Reestman J, et al. SMS reminders improve
adherence to oral medication in type 2 diabetes patients who are real
time electronically monitored. Int J Med Inform. 2012;81(9):594-604.
36. Lin H, Wu X. Intervention strategies for improving patient adherence to
follow-up in the era of mobile information technology: a systematic review
and meta-analysis. PLoS One. 2014;9(8):e104266.

Counseling Points Multiple Sclerosis - Winter 2015

Table of Contents for the Digital Edition of Counseling Points Multiple Sclerosis - Winter 2015